Garadacimab - CSL Behring
Alternative Names: ANDEMBRY; Andembry; Anti-FXIIa mAb - CSL Behring; Anti-FXIIa monoclonal antibody - CSL Behring; CSL 312; Factor XIIa antagonist monoclonal antibody - CSL BehringLatest Information Update: 25 Apr 2025
At a glance
- Originator CSL Behring
- Class Antibodies; Antifibrotics; Antithrombotics; Antivirals; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Factor XIIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
- Discontinued COVID 2019 infections; Idiopathic pulmonary fibrosis; Interstitial lung diseases
Most Recent Events
- 18 Apr 2025 Launched for Hereditary angioedema (Prevention) in Japan (SC) - First global launch
- 26 Feb 2025 Registered for Hereditary angioedema (Prevention, In children, In adolescents, In adults, In the elderly) in Switzerland (SC)
- 20 Feb 2025 Registered for Hereditary angioedema (Prevention) in Japan (SC)